Bispecific antibody ASP-2138 demonstrates antitumor efficacy in CLDN18.2-expressing tumors
April 26, 2023
Claudin 18.2 (CLDN18.2) is involved in the formation of tight junctions and is expressed in normal gastric mucosa, maintaining its expression during malignant transformation of the gastric epithelium. It is also aberrantly expressed in other tumor types, such as esophageal, pancreatic and lung adenocarcinoma, making it an attractive target for cancer immunotherapy.